Retatrutide Shows Significant Promise for Fatty Liver Disease in Phase 2a Trial

The global prevalence of Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is rapidly increasing, yet there are currently no approved pharmacological treatments. This condition is characterized by excessive fat accumulation in the liver, which can lead to inflammation, fibrosis, and potentially progress to cirrhosis and liver failure. Existing management strategies primarily rely on lifestyle modifications, underscoring a critical unmet need for effective drug therapies that can reduce liver fat and improve overall liver health.

At week 24, retatrutide demonstrated a dose-dependent and statistically significant reduction in hepatic fat fraction (HFF) compared to placebo. The 1 mg dose resulted in a 50.6% reduction, 4 mg in a 74.1% reduction, 8 mg in an 81.7% reduction, and 12 mg in an 81.9% reduction, with all active treatment groups showing p<0.001 versus placebo. The 12 mg dose of retatrutide led to MASLD resolution (defined as HFF <5%) in an impressive 89.6% of participants at week 24, starkly contrasting with only 9.2% in the placebo group (p<0.001). By week 48, MASLD resolution was sustained or achieved in 80.8% to 92.8% across the retatrutide groups, and 48.1% to 63.9% of patients experienced an improvement of at least 1 stage in liver fibrosis without worsening of MASLD. Additionally, significant reductions in body weight (up to 24.2% at week 48 with 12 mg), ALT (up to 50.5%), and AST (up to 45.4%) were observed, indicating broad metabolic benefits. The most common adverse events were gastrointestinal-related, generally mild to moderate, and consistent with other incretin-based therapies.